Berberine Treat Metabolic Syndrome in Schizophrenia

Inclusion Criteria: 1. subjects with the diagnosis of schizophrenia depend on Statistical Manual, Fifth Edition (DSM-5) ; 2. Female subjects aged 18-60 years; 3. monotherapy of atypical antipsychotics for 2 weeks or more , including olanzapine, clozapine, risperidone, and perphenazine； 4. subjects with diagnosis of metabolic syndrome depending on guidelines for the prevention and treatment of dyslipidemia in Chinese adults in 2007; 5. the subjects and their guardians sign the informed consent agreement. Exclusion Criteria: 1. subjects with diagnosis of other psychiatric disorders except schizophrenia depend on DSM-5; 2. chronic organic diseases involving any central nervous system, such as tumors and inflammation, brain trauma, active seizures, vascular diseases, Parkinson's disease, myasthenia gravis, and other degenerative diseases; 3. a history of gastrointestinal surgery or the presence of any possibility of interfering with the absorption, distribution, metabolism, or excretion of drugs situation; 4. used long-acting antipsychotic drugs or receive electroconvulsive therapy (MECT) or receive transcranial magnetic stimulation therapy in the last 1 months; 5. serious physical diseases, including uncontrolled hypertension, severe cardiovascular, cerebrovascular, and pulmonary diseases, thyroid diseases, etc; 6. currently receiving anti-inflammatory or immunosuppressive treatment, including oral steroids; 7. a history of chronic infection, including tuberculosis, AIDS and hepatitis; 8. allergic to berberine,or hemolytic anemia or glucose -6- phosphate dehydrogenase deficiency; 9. pregnant women, lactating women； 10. participants were involved in other clinical trials within 1 months prior to the signing of informed consent 11. other reasons judged by the researchers to be inappropriate for the clinical study.